Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., April 16, 2020 -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today.
As of late, it has definitely been a great time to be an investor Agios Pharmaceuticals
A collection of art showing how anarchists and other rebels are responding to the pandemic and the authoritarian power grabs that accompany it.
On Tuesday, Agios Pharmaceuticals reached an important technical milestone, with its Relative Strength (RS) Rating entering into the 80-plus percentile with an upgrade to 85, up from 64 the day before. Agios Pharmaceuticals is trying to complete a consolidation with a 54.78 entry. Biomarin Pharmaceutical, Corcept Therapeutics and Genmab are among the top 5 highly rated stocks within the group.
Agio Healthcare Division Reflects Company's Commitment to Cybersecurity Protection for Healthcare Industry. The demarcation of Agio Healthcare represents a stronger commitment to serving healthcare at a time when the industry is at the societal forefront figh…
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
AGIO earnings call for the period ending March 31, 2020.
The demarcation of Agio Healthcare represents a stronger commitment to serving healthcare at a time when the industry is at the societal forefront fighting COVID-19. NEW YORK, April 30, 2020 /PRNewswire/ -- Agio , a leading provider of cybersecurity and manag…
Shareholders in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) may be thrilled to learn that the analysts have just...
AGIO earnings call for the period ending March 31, 2020.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) defied analyst predictions to release its quarterly results, which were...
For the first time ever, investment firm RBC Capital released its Small-Cap Growth Idea list, made up of stocks with market caps below $5 billion at the time of publishing, and average daily trading volumes of $10 million. Each name scored one of the coveted spots on the list because the firm’s analysts believe it has “either an attractive normalized growth story or strong durable growth characteristics.”After using TipRanks’ database to get the lowdown on RBC’s top picks, we were able to pinpoint two stocks that have earned support from other analysts as well, enough so to be given a “Strong Buy” consensus rating. Not to mention both names could see substantial gains in the twelve months ahead. Here’s the full scoop.Agios Pharmaceuticals (AGIO)Leveraging its expertise in cellular metabolism and precision medicine, Agios has developed an impressive product pipeline that includes therapies to target cancer and other rare genetic diseases. So far, April has been kind to this healthcare name, with it up 18% since the first of the month. RBC’s take? More gains are on the horizon.Weighing in on AGIO for RBC, 5-star analyst Kennen MacKay argues that while somewhat “controversial," the company’s pyruvate kinase deficiency (PKD) program could be the key to its success. Currently, there aren’t any available treatment options for PKD, which is a rare and severe hemolytic anemia. MacKay doesn’t dispute that AGIO’s mitapivat (AG-348) therapy is a known aromatase inhibitor, which could cause hormonal imbalances, but he points out that during the Phase 2 study, hormones stayed at relatively normal levels.MacKay added, “We view completion of enrollment for two Phase 3 trials (ACTIVATE and ACTIVATE-T) positively with topline expected by YE:20 and see a high 70% probability of success given limited alternatives for these patients. The Phase 3 responses to mitapivat could be superior to Phase 2 response rates as the Phase 3 study excludes patients with 2 non-missense mutations in PKD. We see the potential for de-risking of mitapivat in other hemolytic anemias such as sickle cell disease and thalassemia with mid-2020 updates at the EHA conference.” As a result, peak global PKD sales could reach $880 million in 2020.If that wasn’t enough, MacKay believes its Tibsovo drug represents a key point of strength for the company. While Tibsovo's IDH1mut acute myeloid leukemia (AML) market is smaller than its Idhifa drug’s IDH2mut market, the analyst thinks AGIO’s full ownership of Tibsovo makes it the more valuable asset as Idhifa was developed with Celgene.“We view Tibsovo's approval in 1L AML ineligible for intensive therapy as positive and combination with Aza in 1L AML as practice-changing. We see use in cholangiocarcinoma helping drive Tibsovo value beyond AML,” MacKay commented.With several other possible catalysts fast approaching, it’s no wonder MacKay stayed with the bulls. Along with an Outperform rating, the top analyst kept a $69 price target on the stock, implying 73% upside potential. (To watch MacKay’s track record, click here)In general, the rest of the Street is on the same page. 6 Buys and 2 Hold ratings received in the last three months add up to a Strong Buy consensus rating. At $63.71, the average price target suggests 52% upside potential. (See Agios stock analysis on TipRanks)eHealth, Inc. (EHTH)Switching gears now, eHealth is the largest private health insurance marketplace in the U.S. According to RBC, the stock, which is already up 26% year-to-date, could see its share price grow even more as it’s the only name in the firm’s coverage universe that should escape COVID-19's impact.5-star analyst Frank Morgan believes that because people will continue to reach age 65, EHTH’s addressable market stands to grow. He added, “As these newly-Medicare eligible continue to choose Medicare Advantage over traditional FFS Medicare, eHealth’s growth potential should accelerate. And importantly, as a multi-carrier Medicare Advantage broker, eHealth has no medical underwriting risk.”Every day, almost 10,000 senior citizens age into the Medicare program, with Medicare Advantage penetration slated to increase from 33% currently to about 50% at some point. As a result, Morgan thinks the opportunity for EHTH will expand and rapid changes in plan design and increasing complexity will make its tools more valuable to customers. Additionally, the company’s product enables complete transparency, which could help it compete with other insurance carriers, healthcare.gov and third-party aggregators/call centers.“In addition to opportunities for further membership growth, we believe eHealth is positioned to drive further improvement in per-member economics, including increased lifetime value through better retention, reduced marketing costs through increased use of direct marketing channels vs. third-party lead generation, and lower customer care costs through increased usage of online enrollment vs. its traditional call center approach,” Morgan stated.Even though EHTH has to predict the life time value (LTV) of its commission revenue streams earned from Medicare Advantage and other carriers, Morgan calls its expectations “conservative”. To this end, the analyst tells investors he remains optimistic, maintaining an Outperform call and $166 price target. This target brings the upside potential to 44%. (To watch Morgan’s track record, click here)Similarly, other analysts have high hopes when it comes to EHTH’s long-term growth prospects. With 100% Street support, or 8 Buy ratings to be exact, the message is clear: EHTH is a Strong Buy. Should the $177.13 average price target be met, shares could be in for a 47% twelve-month gain. (See eHealth stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
– Data Supporting Utility of TIBSOVO® in AML and MDS Also Accepted for Presentation – – Agios to Host Investor Webcast on June 12 at 7:30 a.m. ET – CAMBRIDGE, Mass., May 14,.
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 65.29% and 182.24%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Agio, a leading provider of cybersecurity and managed IT services, announces the division of Agio Healthcare, exclusively dedicated to offering the company's portfolio suite of cybersecurity services to the healthcare industry.
Technically speaking, the S&P 500 has cleared major resistance, rising to a potentially consequential test of its 200-day moving average, writes Michael Ashbaugh.
Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products issued a positive opinion on the company’s application for orphan drug designation for its investigational medicine mitapivat as a potential treatment for pyruvate kinase (PK) deficiency, a rare, debilitating, hemolytic anemia. Mitapivat was previously granted orphan drug designation by the United States Food and Drug Administration.
CAMBRIDGE, Mass., May 13, 2020 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today.
– TIBSOVO® Is the First and Only IDH1 Inhibitor to Be Evaluated in a Phase 3 Clinical Trial for IDH1-Mutant Cholangiocarcinoma – CAMBRIDGE, Mass., May 19, 2020 -- Agios.
Gone searching for "free online PowerPoint templates?" This tutorial has you covered. Those free options might suffice when costs are your primary focus.But, you owe it to yourself to check...
Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today reported business highlights and financial results for the first quarter ended March 31, 2020. In addition, Agios provided an update on its response to the global COVID-19 pandemic and the expected impact on its business operations. “Though there is no modern playbook for a crisis like the COVID-19 pandemic, we moved quickly to reduce the risk of our team’s and communities’ exposure to the virus and took action to enable uninterrupted access to our commercial and clinical medicines for the patients who are counting on us,” said Jackie Fouse, Ph.D., chief executive officer at Agios.
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29)• Arvinas Inc (NASDAQ: ARVN) • Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) • Bio-Rad Laboratories, Inc. Cla…
The City of Philadelphia and the Philadelphia Industrial Development Corporation (PIDC) just released lists of all of the local businesses that have received money from […] The post Here Are All the Small Businesses That Have Received Money from Philly’s Coro…
DUBLIN, April 30, 2020 /PRNewswire/ -- The "Outdoor Furniture & Grills - 7th Edition" report has been added to ResearchAndMarkets.com's offering. This study analyzes US markets for outdoor furniture and grill products. Specific products covered include: outdo…
Agios (AGIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
A selection of exercises, rituals, and ways of preparing you can use to reconnect with your agency and ground yourself as we face the pandemic.
Q1 2020 Agios Pharmaceuticals Inc Earnings Call
Learn how to get the most value out of your disaster-recovery-as-a-service investment by conducting a thorough business impact analysis and following a few simple steps.
CAMBRIDGE, Mass., May 12, 2020 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today.
We report on multicolor excitation experiments with color centers in hexagonal boron nitride at cryogenic temperatures. We demonstrate controllable optical switching between bright and dark states of color centers emitting around 2 eV. Resonant, or quasi-reso…
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Is (AGIO) Outperforming Other Medical Stocks This Year?